Tumor Necrosis Factor

TNFRSF1A

Tumor necrosis factor receptor 1, Tumor necrosis factor receptor type I, TNF-RI, TNFR-I, p55

Homo sapiens (Human)

Partial

2158862; 2158863; 1702293; 1698610; 2170974; 1315717; 14702039; 19906316; 16541075; 15489334; 8015639; 2153136; 9557650; 10356400; 10542291; 10359574; 9915703; 15465831; 21976655; 22801493; 8387891; 8939750; 10199409; 10902757; 11443543; 13130484; 14610673

21.2 kDa

Tag-Free

E.Coli

>97% as determined by SDS-PAGE and HPLC.

0.2 μm filtered PBS, pH 7.4 ,lyophilized

Less than 1.0 EU/μg as determined by LAL method.

Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the TNF-alpha mediated cytotoxicity in the L-929 cells is less than 0.05 μg/ml, corresponding to a specific activity of >2x10⁴ IU/mg in the presence of 0.25 ng/mL of rHuTNF-alpha.

TNR1A_HUMAN

Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.

IYPSGVIGLV PHLGDREKRD SVCPQGKYIH PQNNSICCTK CHKGTYLYND CPGPGQDTDC RECESGSFTA SENHLRHCLS CSKCRKEMGQ VEISSCTVDR DTVCGCRKNQ YRHYWSENLF QCFNCSLCLN GTVHLSCQEK QNTVCTCHAG FFLRENECVS CSNCKKSLEC TKLCLPQIEN VKGTEDSGTT

22-211aa

Cancer